Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of pomalidomide with low-dose dexamethasone and cyclophosphamide in relapsed or refractory multiple myeloma
2013-003678-29Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2014
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by University Hospital Tübingen. Primary endpoint: Response Rate. Started Jan 2014; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-003678-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003678-29.